Is LEGN a Buy? What to Consider in 2026
Short answer
The bull case for Legend Biotech (LEGN) rests on CARVYKTI commercial ramp: CARVYKTI net trade sales reached about $1.9 billion in 2025 and rose roughly 62 percent year over year in Q1 2026, with ex-US sales growing far faster than US sales off a smaller base. Revenue (TTM, collaboration/license) is ~$1.1B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. Whether LEGN is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Legend Biotech is a global cell-therapy company best known for CARVYKTI (ciltacabtagene autoleucel, or cilta-cel), a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. It develops and commercializes CARVYKTI in a 50/50 profit-and-cost-sharing collaboration with Johnson & Johnson, so Legend's reported revenue shows up largely as collaboration and license income rather than direct product sales. The company also runs an earlier-stage pipeline of other cell therapies and solid-tumor programs, but CARVYKTI drives essentially all of the current commercial narrative. The investment picture is a scaling-into-profitability story. CARVYKTI reached roughly $1.9 billion in global net trade sales in 2025 and grew about 62 percent year over year in the first quarter of 2026, helped by earlier-line use and expanded manufacturing across more than 300 treatment sites. Legend has been narrowing its losses toward adjusted breakeven while holding a sizable cash cushion, but it remains dependent on one franchise, on J&J as its commercial partner, and on a competitive multiple-myeloma market. The stock trades as a high-multiple growth biotech, so results and the pace toward sustained profit matter a great deal.
What's the case for buying LEGN?
1. CARVYKTI commercial ramp
CARVYKTI net trade sales reached about $1.9 billion in 2025 and rose roughly 62 percent year over year in Q1 2026, with ex-US sales growing far faster than US sales off a smaller base. The franchise is now available in 18 markets and more than 300 sites, and management has pointed to expanding manufacturing capacity as the key throughput lever. Continued volume growth is the single largest driver of the story.
2. Move to earlier lines of therapy
Approvals expanding CARVYKTI into earlier treatment lines widen the eligible patient pool well beyond heavily pretreated patients. Earlier use, if supported by durable outcomes data, is what supports the multibillion-dollar sales trajectory analysts model. Adoption depends on physician comfort with CAR-T logistics versus off-the-shelf alternatives.
3. Path to profitability
Legend narrowed its net loss substantially in Q1 2026 (adjusted net loss of about $10.5 million) and reported a full-year 2025 adjusted net loss of roughly $33 million, signaling it is approaching adjusted breakeven. The J&J profit split means margin leverage builds as CARVYKTI scales. Reaching and sustaining GAAP profit remains the central proof point investors are watching.
4. Pipeline optionality
Beyond CARVYKTI, Legend is advancing earlier-stage cell therapies including next-generation and solid-tumor programs. These are largely unproven and years from meaningful revenue, so they function as long-dated optionality rather than a current earnings contributor. Any clinical readout that de-risks a second franchise would matter given the current single-product concentration.
What are the risks to LEGN?
Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. The multiple-myeloma market is increasingly crowded, with competing CAR-T therapies like Bristol Myers Squibb's Abecma and off-the-shelf BCMA bispecific antibodies such as J&J's Tecvayli and Pfizer's Elrexfio that avoid CAR-T's manufacturing and logistics burden. CAR-T therapies also carry serious safety considerations and manufacturing and capacity constraints that can cap growth. The company is only near breakeven and still posts losses, so any sales miss, pricing pressure, or safety signal can move the stock sharply. As a China-founded, US-listed ADR, it also carries geopolitical, supply-chain, and regulatory exposure that pure-play US biotechs do not.
How is LEGN valued? (as of JULY 2026)
Snapshot for LEGN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM, collaboration/license): ~$1.1B
- CARVYKTI net trade sales (FY2025, global): ~$1.9B
- Q1 2026 total revenue: ~$305M
- FY2025 adjusted net loss: ~$33M
- Cash & time deposits (Q1 2026): ~$835M
- Market cap: ~$5.8B
LEGN trades as a high-multiple growth biotech whose revenue is recognized mainly as collaboration and license income under the J&J profit split, distinct from CARVYKTI's roughly $1.9 billion in 2025 global net trade sales. The company is approaching adjusted breakeven while still reporting losses, so the valuation reflects expectations for continued CARVYKTI growth rather than current earnings. Wall Street price targets vary widely, underscoring how much hinges on the pace of the ramp.
How do you decide if LEGN is a buy?
Rather than asking whether LEGN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold LEGN indirectly through an index or sector ETF before adding more.
For the full picture, see the LEGN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about LEGN against your real portfolio and see your actual exposure before deciding.
The bottom line on LEGN
The bottom line: Legend Biotech's story right now is CARVYKTI commercial ramp, with revenue (ttm, collaboration/license) at ~$1.1B. If you believe that narrative continues, the call is about sizing LEGN sensibly and checking overlap with what you own; if you doubt it (the risk: legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around LEGN with Walnut
Use Legend Biotech as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is LEGN a good stock to buy right now?
+
The case for Legend Biotech right now is CARVYKTI commercial ramp, with revenue (ttm, collaboration/license) at ~$1.1B. If you believe that thesis holds, LEGN is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Legend Biotech do?
+
Legend Biotech is a global cell-therapy company best known for CARVYKTI (ciltacabtagene autoleucel, or cilta-cel), a one-time BCMA-directed CAR-T treatment for relapsed or refracto
What are the main risks of LEGN?
+
Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. The multiple-myeloma market is increasingly crowded, with competing CAR-T therapies like Bristol Myers Squibb's Abecma and off-the-shelf BCMA bispecific antibodies such as J&J's Tecvayli and Pfizer's Elrexfio that avoid CAR-T's manufacturing and logistics burden. CAR-T therapies also carry serious safety considerations and manufacturing and capacity constraints that can cap growth. The company is only near breakeven and still posts losses, so any sales miss, pricing pressure, or safety signal can move the stock sharply. As a China-founded, US-listed ADR, it also carries geopolitical, supply-chain, and regulatory exposure that pure-play US biotechs do not.
What does Legend Biotech do?
+
Legend Biotech is a cell-therapy company whose flagship product is CARVYKTI, a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. It co-develops and shares profits on CARVYKTI with Johnson & Johnson and runs an earlier-stage pipeline of other cell therapies.
Is LEGN a US-listed stock?
+
Yes. Legend Biotech trades on the Nasdaq under the ticker LEGN as an American Depositary Receipt. The company was founded in China and is legally domiciled outside the US, which adds ADR and geopolitical considerations for investors.
What is CARVYKTI and why does it matter so much?
+
CARVYKTI (cilta-cel) is a personalized CAR-T therapy that reengineers a patient's own T cells to attack BCMA-expressing myeloma cells. It generated roughly $1.9 billion in global net trade sales in 2025 and is essentially the entire commercial story, so its trajectory drives the stock.
How does Legend make money from CARVYKTI?
+
Legend shares CARVYKTI's costs and profits with Johnson & Johnson under a collaboration. As a result, its reported revenue appears largely as collaboration and license income rather than direct product sales, and it captures roughly half of the franchise economics.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell LEGN; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.